Literature DB >> 17454603

Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes.

J M Jørgensen1, F B Sørensen, K Bendix, J L Nielsen, M L Olsen, A M D Funder, F d'Amore.   

Abstract

The aim of the study was to evaluate angiogenesis in different subtypes of non-Hodgkin's lymphoma (NHL) and to correlate angiogenic scores to clinical endpoints. Pre-therapeutic lymph node biopsies from 308 patients with NHL [107 follicular B-cell lymphoma (FL), 94 diffuse large B-cell lymphoma (DLBCL), 107 peripheral T-cell lymphoma (PTCL)] were studied. Microvessels were scored according to the Chalkley and microvessel density method (MVD) methods. Vascular endothelial growth factor (VEGF) protein expression was evaluated by immunohistochemistry. Both Chalkley and MVD methods showed, that the lymphoma subtypes differed significantly in angiogenic scores (P < 0.001). Angiogenic scores in tumor area were highest in PTCL, and lowest in FL. However, a remarkable high microvessel density was found in interfollicular areas of FL. In FL, high interfollicular MVD scores predicted progressive disease and poorer overall and event-free survival (P = 0.024 and 0.013). High interfollicular Chalkley scores correlated with transformation to DLBCL (P = 0.01). VEGF expression was detected in all NHL subtype, and the strongest expression was found in PTCL. In FL, patients with diffuse VEGF expression in lymphoma cells had poorer overall survival than those with focal expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454603     DOI: 10.1080/10428190601083241

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  20 in total

1.  The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas.

Authors:  Jelena Jelicic; Milena Todorovic Balint; Maja Perunicic Jovanovic; Novica Boricic; Marjan Micev; Jelena Stojsic; Darko Antic; Bosko Andjelic; Jelena Bila; Bela Balint; Sonja Pavlovic; Biljana Mihaljevic
Journal:  Pathol Oncol Res       Date:  2016-01-11       Impact factor: 3.201

2.  Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.

Authors:  Ranjana H Advani; Fangxin Hong; Sandra J Horning; Brad S Kahl; Judith Manola; Lode J Swinnen; Thomas M Habermann; Kristen Ganjoo
Journal:  Leuk Lymphoma       Date:  2011-12-05

Review 3.  Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2011-09-23       Impact factor: 3.064

4.  High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.

Authors:  Teresa M Cardesa-Salzmann; Luis Colomo; Gonzalo Gutierrez; Wing C Chan; Dennis Weisenburger; Fina Climent; Eva González-Barca; Santiago Mercadal; Leonor Arenillas; Sergio Serrano; Ray Tubbs; Jan Delabie; Randy D Gascoyne; Joseph M Connors; Jose L Mate; Lisa Rimsza; Rita Braziel; Andreas Rosenwald; Georg Lenz; George Wright; Elaine S Jaffe; Louis Staudt; Pedro Jares; Armando López-Guillermo; Elias Campo
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

5.  Vascularization predicts overall survival and risk of transformation in follicular lymphoma.

Authors:  Pedro Farinha; Alastair H Kyle; Andrew I Minchinton; Joseph M Connors; Aly Karsan; Randy D Gascoyne
Journal:  Haematologica       Date:  2010-08-16       Impact factor: 9.941

6.  Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.

Authors:  Michael Medinger; Natalie Fischer; Alexandar Tzankov
Journal:  J Oncol       Date:  2010-05-24       Impact factor: 4.375

Review 7.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

Review 8.  Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.

Authors:  J Ruan; K Hajjar; S Rafii; J P Leonard
Journal:  Ann Oncol       Date:  2008-12-16       Impact factor: 32.976

9.  Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma.

Authors:  Lan-Ping Diao; Xiao-Ming Yu; Yu-Huan Gao; Yan Li; Hai-Sheng Liu; Li-Hong Liu; Rong-Miao Zhou; Na Wang; Li-Li Wu; Shi-Jie Wang
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-01       Impact factor: 4.553

10.  Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.

Authors:  Rena Buckstein; John Kuruvilla; Neil Chua; Christina Lee; David A Macdonald; Abdulwahab J Al-Tourah; Alison H Foo; Wendy Walsh; S Percy Ivy; Michael Crump; Elizabeth A Eisenhauer
Journal:  Leuk Lymphoma       Date:  2011-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.